Richard Jove
- Oncology top 0.01%
- Molecular Biology top 0.05%
- Immunology top 0.05%
- Cancer Research top 0.05%
- Pathology and Forensic Medicine top 0.05%
- Co-authors
- Hua YuJames TurksonDrew M. PardollRalf BuettnerRoy GarciaTammy BowmanHeehyoung LeeAndreas Herrmann
- Topics
- Cytokine Signaling Pathways and Interactions (124 papers)PI3K/AKT/mTOR signaling in cancer (45 papers)Cancer Mechanisms and Therapy (42 papers)
- Cited by
- OncologyImmunologyCancer Research
- Partner nations
- United StatesGreeceCanada
In The Last Decade
Richard Jove
263 papers receiving 39.8k citations
Hit Papers
Peers
Comparison fields: 5 of 157
- Oncology 21.9k
- Molecular Biology 21.5k
- Immunology 9.9k
- Cancer Research 6.9k
- Pathology and Forensic Medicine 6.2k
Countries citing papers authored by Richard Jove
This map shows the geographic impact of Richard Jove's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Jove with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Jove more than expected).
Fields of papers citing papers by Richard Jove
This network shows the impact of papers produced by Richard Jove. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Jove. The network helps show where Richard Jove may publish in the future.
Co-authorship network of co-authors of Richard Jove
This figure shows the co-authorship network connecting the top 25 collaborators of Richard Jove. A scholar is included among the top collaborators of Richard Jove based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Jove. Richard Jove is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 60 | |
| 2 | 84 | |
| 3 | 105 | |
| 4 | 156 | |
| 5 | 92 | |
| 6 | 92 | |
| 7 | 93 | |
| 8 | 89 | |
| 9 | 51 | |
| 10 | 87 | |
| 11 | 83 | |
| 12 | The Src family kinase inhibitor, dasatinib, inhibits angiogenesis in vitro and in vivo | 3 |
| 13 | 5 | |
| 14 | 151 | |
| 15 | SKI-606, a novel Src kinase inhibitor, blocks migration and invasion of human breast cancer cells | 1 |
| 16 | 183 | |
| 17 | Dasatinib (BMS-354825), a novel multi-targeted kinase inhibitor that blocks tumor cell migration and invasion, is a promising therapeutic agent for metastatic prostate cancer | 2 |
| 18 | 135 | |
| 19 | Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expressionbreakdown → | 505 |
| 20 | 12 |
About Richard Jove
Richard Jove is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology, having authored 264 papers that have together received 40.4k indexed citations. Recurring topics across this work include Cytokine Signaling Pathways and Interactions (124 papers), PI3K/AKT/mTOR signaling in cancer (45 papers) and Cancer Mechanisms and Therapy (42 papers). The work is most often cited by research in Oncology (21.9k citations), Immunology (9.9k citations) and Cancer Research (6.9k citations). Richard Jove has collaborated with scholars based in United States, Greece and Canada. Frequent co-authors include Hua Yu, James Turkson, Drew M. Pardoll, Ralf Buettner, Roy Garcia, Tammy Bowman, Heehyoung Lee, Andreas Herrmann, Linda Mora and Guilian Niu. Their work appears in journals such as Science, Cell and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.